Publications by authors named "Angelo Martignetti"

Claim this Profile
P
Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial.
Luca Livraghi, Francesca Martella, Matteo Ghilli, Catia Angiolini, Simonetta Magnanini, Angelo Martignetti

Eur J Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Francesco Massari, Matteo Santoni, Hideki Takeshita, Yohei Okada, Jose Carlos Tapia, Angelo Martignetti

Cancer Immunol Immunother· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.
Matteo Santoni, Francesco Massari, Hideki Takeshita, Jose Carlos Tapia, Michele Dionese, Angelo Martignetti

Clin Exp Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Ondřej Fiala, Sebastiano Buti, Hideki Takeshita, Yohei Okada, Francesco Massari, Angelo Martignetti

Cancer Immunol Immunother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.
Matteo Santoni, Francesco Massari, Sergio Bracarda, Enrique Grande, Marc R Matrana, Angelo Martignetti

Eur Urol Focus· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma.
Matteo Santoni, Francesco Massari, Marc R Matrana, Umberto Basso, Ugo De Giorgi, Angelo Martignetti

Eur J Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
Matteo Santoni, Gaetano Aurilio, Francesco Massari, Enrique Grande, Marc R Matrana, Angelo Martignetti

Clin Genitourin Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.
Roberto Moretto, Daniele Rossini, Iolanda Capone, Alessandra Boccaccino, Federica Perrone, Angelo Martignetti

Clin Colorectal Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
Matteo Santoni, Francesco Massari, Sergio Bracarda, Giuseppe Procopio, Michele Milella, Angelo Martignetti

Diagnostics (Basel)· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors.
Matteo Santoni, Daniel Y Heng, Sergio Bracarda, Giuseppe Procopio, Michele Milella, Angelo Martignetti

Cancers (Basel)· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers.
Matteo Santoni, Alessia Cimadamore, Francesco Massari, Francesco Piva, Gaetano Aurilio, Angelo Martignetti

Cancers (Basel)· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.
Lorenzo Rossi, Chiara Biagioni, Amelia McCartney, Ilenia Migliaccio, Giuseppe Curigliano, Angelo Martignetti

Breast Cancer Res· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.
Gianluca Masi, Caterina Vivaldi, Lorenzo Fornaro, Sara Lonardi, Piero Buccianti, Angelo Martignetti

Eur J Cancer· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancer.
Beatrice Borelli, Roberto Moretto, Sara Lonardi, Andrea Bonetti, Carlotta Antoniotti, Angelo Martignetti

ESMO Open· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tivozanib for the treatment of renal cell carcinoma.
Matteo Santoni, Francesco Massari, Francesco Piva, Francesco Carrozza, Vincenzo Di Nunno, Angelo Martignetti

Expert Opin Pharmacother· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
Federica Marmorino, Lisa Salvatore, Cecilia Barbara, Giacomo Allegrini, Lorenzo Antonuzzo, Angelo Martignetti

Br J Cancer· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secondary bone marrow malignancies after adjuvant chemotherapy for breast cancer: a report of 2 cases and a review of the literature.
David Rossi, Donatella Sarti, Lara Malerba, Silvia Tommasoni, Giuseppe Visani, Angelo Martignetti

Tumori· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triple-negative breast cancer: current state of the art.
Francesca Rastelli, Sandra Biancanelli, Amalia Falzetta, Angelo Martignetti, Camilla Casi

Tumori· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Art therapy with cancer patients during chemotherapy sessions: an analysis of the patients' perception of helpfulness.
Silvia Forzoni, Michela Perez, Angelo Martignetti, Sergio Crispino

Palliat Support Care· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer.
Maria Giulia Zampino, Elena Magni, Cristian Massacesi, Alberto Zaniboni, Angelo Martignetti

Cancer· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients.
Olga Minenkova, Andrea Pucci, Emiliano Pavoni, Amedeo De Tomassi, Paola Fortugno, Angelo Martignetti

Int J Cancer· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI).
Claudia Pizzi, Michele Caraglia, Maria Cianciulli, Antonietta Fabbrocini, Anna Libroia, Angelo Martignetti

Anticancer Res· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma.
Giovannella Palmieri, Liliana Montella, Mario Milo, Rosaria Fiore, Edoardo Biondi, Angelo Martignetti

Am J Clin Oncol· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Somatostatin analogs and prednisone in advanced refractory thymic tumors.
Giovannella Palmieri, Liliana Montella, Angelo Martignetti, Pietro Muto, Dolores Di Vizio

Cancer· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis